New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept

Figure 3

Heterogeneity analyses. (a) MS () analyses of etanercept (red) and rituximab (black), (b) glycan heterogeneity by HILI-UPLC of Infinitam (blue) and the reference product (red), and (c) charge heterogeneity by cIEF of Infinitam (blue), reference product (red), and rituximab (black).

(a)

(b)

(c)